PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
暂无分享,去创建一个
Liu Cao | Xiaoman Li | Changjing Wu | Nianci Chen | Huadi Gu | A. Yen | E. Wang | Liang Wang | Liu Cao | Enhua Wang | Xiaoman Li | Changjing Wu | Nianci Chen | Huadi Gu | Allen Yen | Liang Wang
[1] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[2] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[3] T. Cloughesy,et al. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance , 2014, Cancer biology & medicine.
[4] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[5] Alona Muzikansky,et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Ng,et al. Effects of cotransfection of antisense‐EGFR and wild‐type PTEN cDNA on human glioblastoma cells , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.
[7] Paul Workman,et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.
[8] Li Zhao,et al. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.
[9] Alessia Pica,et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Debatin,et al. A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy , 2014, Molecular and Cellular Therapies.
[11] W. Yung,et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas , 2009, Molecular Cancer Therapeutics.
[12] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[13] Jayson A. Neil,et al. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. , 2015, Advances in biological regulation.
[14] R. McLendon,et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. , 2010, Neuro-oncology.
[15] J. Barnholtz-Sloan,et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.
[16] O. Delattre,et al. Targeting the PI3K p110α Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration , 2008, Clinical Cancer Research.
[17] K Y Hui,et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.
[18] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[19] J. Tabernero,et al. Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs , 2010, Oncotarget.
[20] A. Unterberg,et al. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. , 2006, Cancer treatment reviews.
[21] N. Hay. Interplay between FOXO, TOR, and Akt. , 2011, Biochimica et biophysica acta.
[22] P. Richardson,et al. Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia , 2010, Clinical Cancer Research.
[23] H. Gach,et al. Akt signaling is required for glioblastoma maintenance in vivo. , 2011, American journal of cancer research.
[24] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[25] K. Aldape,et al. Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.
[26] William A Weiss,et al. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. , 2012, Methods in molecular biology.
[27] P. Mischel,et al. mTORC2 in the center of cancer metabolic reprogramming , 2014, Trends in Endocrinology & Metabolism.
[28] M. Pincus,et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. , 2006, Frontiers in bioscience : a journal and virtual library.
[29] E. Holland,et al. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. , 2005, Cancer research.
[30] J. Hainsworth,et al. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. , 2012, Clinical advances in hematology & oncology : H&O.
[31] G. Reifenberger,et al. Genetic alteration and expression of the phosphoinositol‐3‐kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas , 2005, Neuropathology and applied neurobiology.
[32] M. Delorenzi,et al. Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial , 2011, Molecular Cancer Therapeutics.
[33] C. Kang,et al. Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas , 2010, Clinical Neurology and Neurosurgery.
[34] A. Sami,et al. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding , 2013, Tumor Biology.
[35] W. Yung,et al. Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells , 2011, Clinical Cancer Research.
[36] David M Sabatini,et al. An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.
[37] P. Wipf,et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. , 2004, Molecular cancer therapeutics.
[38] S. Toms,et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme , 2010, Journal of Neuro-Oncology.
[39] The Cancer Genome Atlas Research Network. Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2013, Nature.
[40] C. Beaudry,et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis , 2003, Journal of Cell Science.
[41] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[42] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[43] K. Shokat,et al. Chemically targeting the PI3K family. , 2007, Biochemical Society transactions.
[44] S. Weiss,et al. Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival , 2014, Clinical Cancer Research.
[45] Adam Dicker,et al. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. , 2004, International journal of radiation oncology, biology, physics.
[46] Q. Gao,et al. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma , 2013, Expert opinion on investigational drugs.
[47] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[48] Susan M. Chang,et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. , 2014, Neuro-oncology.
[49] A. Clavreul,et al. Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide. , 2015, Drug discovery today.
[50] Lisa L. Smith,et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.
[51] R. Copeland,et al. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. , 2008, The Biochemical journal.
[52] Nahum Sonenberg,et al. Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.
[53] N. Sonenberg,et al. Upstream and downstream of mTOR. , 2004, Genes & development.
[54] A. Degterev,et al. Role of phosphatidylinositol 3,4,5-trisphosphate in cell signaling. , 2013, Advances in experimental medicine and biology.
[55] P. Furet,et al. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. , 2008, Bioorganic & medicinal chemistry letters.
[56] W. Mason,et al. Phase II study of PX-866 in recurrent glioblastoma. , 2012, Neuro-oncology.
[57] W. Yung,et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. , 2010, Neuro-oncology.
[58] J. Dodge,et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.
[59] Debyani Chakravarty,et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.
[60] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[61] P. Vogt,et al. Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[62] M. Karsy,et al. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. , 2009, International journal of oncology.
[63] Forest M White,et al. Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.
[64] Jordi Rodon,et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. J. van den Bent,et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] T. Cloughesy,et al. Glioblastoma: from molecular pathology to targeted treatment. , 2014, Annual review of pathology.
[67] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[68] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[69] T. Cloughesy,et al. Targeted therapy for malignant glioma patients: Lessons learned and the road ahead , 2009, Neurotherapeutics.
[70] G. Powis,et al. Advances with phospholipid signalling as a target for anticancer drug development. , 1995, Acta biochimica Polonica.
[71] I. Kim,et al. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases , 2014, BMC Cancer.
[72] J. Dry,et al. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. , 2011, Biochemical Society transactions.
[73] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[74] William A Weiss,et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.
[75] Y. Hu,et al. PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion , 2007, Oncogene.
[76] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[77] J. Dixon,et al. PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.
[78] P. Wen,et al. Current clinical development of PI3K pathway inhibitors in glioblastoma. , 2012, Neuro-oncology.
[79] C. James,et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.
[80] R. Copeland,et al. Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase , 2008 .
[81] Caterina Giannini,et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[83] H. Wakimoto,et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. , 2011, Cancer research.
[84] H. Burris,et al. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway , 2013, Cancer Chemotherapy and Pharmacology.
[85] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[86] Qiang Wang,et al. ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.
[87] I. Ben-Sahra,et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. , 2011, Cancer research.
[88] R. McLendon,et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma , 2009, Journal of Neuro-Oncology.
[89] J. Engelman,et al. The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[91] Susan M. Chang,et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.
[92] O. Wiestler,et al. Phosphatidylinositol 3′-Kinase/AKT Signaling Is Activated in Medulloblastoma Cell Proliferation and Is Associated with Reduced Expression of PTEN , 2006, Clinical Cancer Research.
[93] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.